To determine the amount of propofol (a sedative drug), needed for sedating patients undergoing Endoscopic retrograde cholangiopancreatography by using a target control infusion pump.
Not Applicable
- Conditions
- Health Condition 1: K87- Disorders of gallbladder, biliarytract and pancreas in diseases classified elsewhere
- Registration Number
- CTRI/2023/09/057623
- Lead Sponsor
- INSTITUTE OF LIVER AND BILIARY SCIENCES
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ASA-1 AND 2 PATIENTS
Exclusion Criteria
DECOMPENSATED LIVER CIRRHOSIS, POST LIVER TRANSPLANT, PATIENTS ALLERGIC TO PROPOFOL AND ITS CONTENTS
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine Target effector concentration (Ce) of Propofol needed to achieve sedation (BIS 50-70) in patients undergoing ERCP.Timepoint: intraprocedural
- Secondary Outcome Measures
Name Time Method TO DETERMINE HEMODYNAMIC PROFILE, RECOVERY PROFILE, TOTAL CONSUMPTION OF PROPOFOL AND ADVERSE EFFECTS OF PROPOFOL INFUSION VIA TCI PUMP IN ERCPTimepoint: PERIPROCEDURA